Johnson & Johnson: the Tylenol recall after seven deaths in Chicago

The situation

On 29 September 1982, 12-year-old Mary Kellerman of Elk Grove Village, Illinois, died within hours of taking an Extra-Strength Tylenol capsule for a cold. The same day Adam Janus, a postal worker from Arlington Heights, died in hospital after taking the same medicine. Two of his relatives took capsules from the same bottle at the family home and died too. Within days, seven people in the Chicago area were dead. Investigators found cyanide in the capsules.

The product led its market. Before the deaths, Tylenol, made by the Johnson & Johnson subsidiary McNeil Consumer Products, held 35 per cent of a $1.2 billion market for analgesics, according to Knowledge at Wharton. After the deaths its share fell to 7 per cent. The company’s chairman, James Burke, had to decide in a few days what a business owes its customers when something it sold has killed them, and he had to decide it before anyone knew who had done it or how.

All the tainted capsules found came from a single batch, and the deaths were all in one metropolitan area. The company could have confined its response to that lot or that city. Instead it stopped production, halted advertising and, on 5 October, began withdrawing Tylenol across the country. Wharton and other sources put the recall at about 31 million bottles. CNBC, using the company’s own spokesman, said 32 million. The cost was reported as more than $100 million, though figures vary widely across sources.

The company then did something less often remembered: it rebuilt the product. Tylenol came back in tamper-resistant packaging, regulators wrote new rules, and by the end of 1983 Tylenol’s market share had returned to 35 per cent. The person who put the poison in the capsules has never been identified. This case looks at how a company made a costly decision on incomplete information, what it did to rebuild trust, and what the episode does and does not prove about corporate crisis management.

Background

Johnson & Johnson and the man in charge

Johnson & Johnson was a large, diversified maker of health products, based in New Brunswick, New Jersey. James Burke joined in 1953 as a product director, became president in 1973, and served as chief executive and chairman from 1976 to 1989. During his years as leader, annual sales more than tripled to $9 billion, net income rose nearly fivefold, and the company grew from 37 countries to 54, according to the Associated Press obituary published in 2012.

The credo

The company ran its operations through a short written statement known as the credo. It sets out the company’s responsibilities in an order: first to customers, then to employees, then to the communities where they live, and finally to stockholders. Knowledge at Wharton reports that Burke later said the credo “gave me the ammunition I needed to persuade shareholders” to pay for the recall, a remark he made in his 2004 book Lasting Leadership. In the same book he wrote: “The credo helped sell it.” The credo did not make the decision for him. It gave him a written ranking he could point to when the choice cost money.

What Tylenol was

Tylenol was an acetaminophen painkiller sold without prescription. Its Extra-Strength capsule was a hollow gelatin shell filled with powder. The hollow capsule could be pulled apart and refilled, which is why J&J later moved to solid caplets that are harder to pull apart and alter. The FDA also criticised the packaging of the time. In a rule published in 1982, the agency said that neither bottles nor cartons were sealed or made in a way that required the destruction or visible disturbance of the package to reach the product, according to a quotation from the Federal Register given by HeinOnline.

The industry

In 1982 the market for over-the-counter painkillers was large and brand driven. Tylenol’s 35 per cent share of a $1.2 billion market shows how much of it one product held. A product with that much of a market depends on customers trusting it without checking it.

Regulation was thin. WTKR reports that the FDA issued its first rules on tamper-resistant packaging for over-the-counter drugs in 1982, after the Chicago deaths, and HeinOnline says the rules required visible signs of tampering such as seals, blister packs or breakable caps. Congress made tampering with medicines and other consumer goods a federal crime in 1983.

The retail chain also mattered. Products went from the factory to distributors and then to shops where anyone could handle them. Investigators believe the killer opened capsules, replaced the contents with cyanide and returned the bottles to shelves, according to UPI. That meant the company could not stop the harm at its own gates, and every bottle already in a home or shop was a possible risk.

Communication was another feature of the industry. In 1982 there was no social media. News came through television, radio and newspapers, and a company that wanted to reach the public quickly had to work through journalists. Chicago police drove through the streets using loudspeakers to warn people not to take Tylenol, according to J&J’s communications chief Steve Dnistrian, cited by CNBC. The speed of the news cycle, rather than the speed of the company, set the pace.

The decision

The sources describe what Johnson & Johnson did, not the options it formally weighed. The alternatives below are the obvious ones, framed as such, with what the sources suggest about the case for each.

Limit the action to the affected lot or city

The evidence pointed to a narrow problem. CBS Chicago reports that all the tainted capsules came from one lot, number MC2880, in 50-capsule Extra-Strength bottles with an expiry date of April 1987. No deaths were attributed to tainted Tylenol after 2 October. A company focused on cost could have argued that a Chicago recall dealt with the facts. J&J did take that step first: HeinOnline records a recall of Extra-Strength Tylenol in the greater Chicago area on 1 October, and CBS notes that Mayor Jane Byrne banned the product in the city the same day.

Recall the product nationwide

On 5 October the company went further. Burke, according to Dnistrian’s recollection in the CNBC obituary, announced at a press conference that the company would seize all Tylenol capsules. HeinOnline describes the 5 October recall as covering all Tylenol products, while CNBC and the Associated Press speak of capsules. The sources differ on this point. About 31 million bottles were involved, at a cost of more than $100 million at the time. Dnistrian quoted Burke as saying: “There was just no other way to guarantee public safety.”

The argument for this course was that nobody knew how many bottles were affected or where. Early speculation was that the capsules might have been poisoned inside a J&J plant, rather than after they left it, according to CNBC. A narrow recall would have left the company open to a second death in a place it had not looked.

Defend the brand and wait

The third option was to say little, wait for the investigation and protect the Tylenol name from a general panic. The sources do not suggest J&J seriously considered it. Burke instead chose to share information. According to Knowledge at Wharton, he contacted the heads of each network’s news division to keep them informed and met the directors of the FBI and the FDA.

The cost of choosing

The recall had a price, and the sources disagree about its size. Wharton, HeinOnline and the Associated Press give more than $100 million. EBSCO puts the cost at $240 million. UPI reported that the recall reduced the company’s earnings by $50 million. The figures probably measure different things, for example the value of stock withdrawn, the full cost of recall and relaunch, and the effect on profit. None of the sources explains the differences, so this case gives the range rather than a single figure.

What they did

29 September to 5 October: finding the cause and pulling the product

The link between the deaths and the capsules was made by a public health nurse. WTTW reports that Helen Jensen of Arlington Heights found a Tylenol bottle at the Janus home with six capsules missing. County officials confirmed cyanide in the pills. Chicago removed the product from shelves, the company recalled it locally on 1 October, and on 5 October it announced the national withdrawal. It also set up a hotline and offered a $100,000 reward for information leading to an arrest, according to HeinOnline, and stopped advertising the product, according to EBSCO.

Talking to the public

Burke’s approach was open. The company told the public to avoid Tylenol, spoke to the networks and worked with regulators. Dnistrian told the Associated Press that the company’s transparency during the crisis was extraordinary. People who had bought Tylenol were offered replacements. EBSCO reports that the company offered free replacements for discarded packages through a toll-free number, and later coupons worth $2.50.

Testing the stock

While the recall was under way, the company and the FDA tested bottles. According to WTKR, citing the FDA, J&J tested 1.5 million bottles and found three more unopened bottles contaminated, bringing the total of tampered bottles to 10. That finding supported the view that the product had been altered after leaving the factory, and not by a failure in the plant.

Relaunching in new packaging

Tylenol returned with packaging designed to show interference. WTKR describes the design as a glued-flap box, a plastic ring around the neck of the bottle and a foil seal, and EBSCO adds a warning not to use the product if any seal was broken. The sources disagree about when the relaunch took place. CBS Chicago says Tylenol was back on Chicago shelves in late November 1982. Wharton says the product relaunched about two months after the deaths. EBSCO says Extra-Strength Tylenol was remarketed in January 1983. The sources may be dating the first shelf return and the national relaunch differently, but none of them says so.

Johnson & Johnson also moved from capsules towards solid caplets. HeinOnline dates the introduction of the caplet to 1984, and says capsules were dropped from the line in 1986 after another cyanide death in Westchester County, New York.

What happened

Market share and money

Wharton gives the commercial outcome in three figures. Before the crisis Tylenol held 35 per cent of the analgesic market. After the deaths that fell to 7 per cent. Share recovered to 30 per cent by the middle of 1983 and reached 35 per cent by the end of 1983. Burke later said that the episode helped turn Tylenol into a billion-dollar business. The recall cost at least $100 million, and the sources disagree about how much more.

Public safety and the law

Seven people died, all in the Chicago area, and CBS Chicago reports that no deaths were attributed to tainted Tylenol after 2 October. The FDA counted hundreds of copycat incidents across the country, according to UPI, and consumers went to hospitals out of fear of poisoning. The FDA issued its first tamper-resistant packaging regulations for over-the-counter medicines that year, and the foil seal became common on everyday products. Congress made tampering with consumer products a federal crime in 1983. HeinOnline notes that the first person convicted under the Federal Anti-Tampering Act was Stella Nickell, who in 1988 received two 90-year sentences for cyanide-laced Excedrin that killed her husband and a stranger.

The case that was never closed

The Chicago murders remain unsolved. WTTW reports that Illinois Attorney General Tyrone Fahner formed a special task force soon after the deaths and that an early suspect, Roger Arnold, was later convicted of an unrelated murder but never charged in the Tylenol case. A letter demanding $1 million and threatening more deaths reached J&J on 6 October 1982. James Lewis was arrested in December 1982 in a New York public library and admitted writing the letter. He was convicted of extortion, but WTTW and other sources say no physical evidence ties him to the poisoning. The extortion letters were posted on 1 October, before the deaths were widely known. Lewis died in 2023, and as of 2025 WTTW reports that no one has been charged.

Other views

The company’s own account

Burke credited the credo and the company’s reputation. “I had confidence in J&J and its reputation,” he said, according to Wharton. He wrote that “trust has been an operative word in my life”. The account is consistent and has become the standard telling, and it comes from the man who made the choice. Dnistrian, a company spokesman, added the remark that the company’s transparency was extraordinary. Both statements are testimony from inside the company.

A story with limits

Wharton’s article notes that J&J has had later setbacks that complicate the picture. It lists problems at plants in Fort Washington and Lancaster, Pennsylvania, and in Puerto Rico, linked to recalls of Benadryl and Children’s Tylenol, a hip device recall in 2010, a $158 million agreement with the state of Texas over the marketing of Risperdal, and recalls of sutures and contact lenses. A company that handled one crisis well did not always handle later ones in the same way. The article also describes other firms that responded poorly to their own crises: Coca-Cola in Europe in 1999, Intel over the Pentium chip in 1994 and Firestone over tyre failures in 2000.

There is a more basic difference. In 1982 J&J was the victim of a crime committed by someone else. Later crises at Intel and Firestone involved faults in the companies’ own products. A company that is not at fault may find openness easier than one that is.

Safety experts

Jay Kennedy, a criminal justice professor at Michigan State University, told WTKR that packaging changed how consumers see products and raised awareness of risk, but that the risk of tampering always remains. The FDA itself says over-the-counter packaging cannot be 100 per cent tamper-proof, and Kennedy described counterfeit drugs sold online as a more common concern than tampering. Layered packaging has stood the test of time, he said, but no public data show how often it prevents harm.

Limits of the evidence

The sources disagree on the recall figure, on the number of bottles, on the date of the relaunch and on the ages of some victims, and several of them rely on recollection decades after the event, such as Dnistrian’s account of the press conference. The CBS Chicago and WTTW accounts agree on the victims’ names and the dates. In the sources opened, the market share figures come from a single article. And the case rests on a counterfactual that cannot be tested: no one can say what would have happened to Tylenol if J&J had recalled only in Chicago.

Reading it through a framework

Stakeholder mapping

Stakeholder mapping lists the parties affected by a decision and asks how much power and interest each has. Here the parties were consumers, the families of the dead, retailers, regulators (the FDA and the FBI), the media, employees, and shareholders. The credo ranked them, with customers first and shareholders last, and Burke used that ranking to persuade shareholders to fund the recall.

The map also shows why the choice was more practical than it looks. Consumers held the power to stop buying. Regulators held the power to restrict sales. The media controlled how the story reached the public. By briefing the networks and meeting the FBI and FDA directors, Burke addressed the groups with the most power over the outcome. Shareholders had power too, and the credo was the tool Burke used to persuade them, in his own words, to fund the recall.

Brand equity

Brand equity is the value a name carries beyond the product: awareness, perceived quality, loyalty and associations. Tylenol’s share fell from 35 per cent to 7 per cent in a few weeks, so a large part of that value could vanish quickly, yet it did not disappear. The share returned to 30 per cent by mid 1983 and 35 per cent by the end of the year. A plausible reading is that customers separated the brand from the crime and saw J&J as the one trying to protect them, though the sources offer no survey of customer attitudes to confirm it.

The recall spent money to protect the brand. Withdrawing 31 million bottles told customers the brand valued their safety above its sales, and the new packaging gave them a visible reason to believe it. That is an interpretation, not a measured result, but it fits the order of events and the recovery.

Since then

The packaging changes became permanent. Tamper-resistant seals spread across medicines and food, and federal law makes tampering a crime. Further cases followed: in 1986 a death in Westchester County, New York, was linked to cyanide in Tylenol, and a woman put cyanide in Excedrin, killing her husband and a stranger. J&J stopped selling Tylenol capsules that year, according to HeinOnline.

The criminal case stayed open. Lewis was released in 1995. In 2009 the FBI searched his home in Cambridge, Massachusetts, in what it called a complete review of the evidence. In 2011 investigators sought DNA from Theodore Kaczynski, the Unabomber, who grew up in the Chicago area, and he said he had never had potassium cyanide. The FBI later passed the file to the Arlington Heights police. A UPI report in 2017 quoted Deputy Chief Mike Hernandez saying the case was a high priority and “not gathering dust”. WTTW reports that as of 2025 no one has been charged.

Burke died in 2012 at the age of 87. In 2000 he had received the Presidential Medal of Freedom. CNBC reports that Harvard Business School uses the handling of the crisis as a textbook case. J&J itself has faced further recalls, which Wharton lists.

What to take from it

• Decide who comes first before the crisis begins. The credo gave Burke a written ranking of customers, employees, communities and shareholders that he could use when the decision cost real money.
• When you do not know the cause, act on the worst case. J&J withdrew product nationwide when the evidence pointed to one lot and one city, because it could not rule out a wider problem.
• Talk to the public through the channels they use, early and directly. Burke briefed the news networks and the regulators rather than waiting for them to ask.
• Rebuild the product as well as the message. The new triple-seal packaging gave customers something visible to rely on, and the industry and regulators adopted it.
• Do not draw too much from one good outcome. J&J was the victim of a crime in 1982, the culprit was never found, and the company later faced recalls linked to its own plants.

Questions to think about

1. If the poisoning had been traced to a J&J plant, which of Burke’s decisions would have looked different, and which would have stayed the same?
2. What would a credo have to say before it can really change a decision, and how would you test whether a company follows its own?
3. The recall figure ranges from $50 million to $240 million across sources. How should a manager treat a number that nobody can fix?
4. How would a company today, with social media and instant news, have to change the way it made and announced a decision like Burke’s?

Concepts at work

The case draws on crisis communication, stakeholder analysis and brand equity. Explore them in Insights.

Written from the public sources listed below. Figures are as those sources report them.